LPCN News

Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +2.55%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciencesread more...

Testosterone replacement therapy has largely relied on delivery methods that come with practical tradeoffs. Injections require needles and can cause injection-site reactions, while topical gels can be messy and carry a risk of transferring testosterone to others through skin contact. An oral treatment that does not require dose titration offers another approach in a Canadian market where more than 700,000 testosterone replacement therapy prescriptions are written annually.Shares of Lipocine Inc. (NASDAQ: LPCN) are moving higher Wednesday after the company announced that Health Canada has ...

Testosterone replacement therapy has largely relied on delivery methods that come with practical tradeoffs. Injections require needles and can cause injection-site reactions, while topical gels can be messy and carry a risk of transferring testosterone to others through skin contact. An oral treatment that does not require dose titration offers another approach in a Canadian market where more than 700,000 testosterone replacement therapy prescriptions are written annually.Shares of Lipocine Inc. (NASDAQ: LPCN) are moving higher Wednesday after the company announced that Health Canada has ...

Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement TherapyPR NewswireSALT LAKE CITY, Oct. 7, 2026SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a...

Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPR NewswireSALT LAKE CITY, Sept. 14, 2026 Study informed by encouraging exploratory efficacy findings and a...

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SALT LAKE CITY, Sept. 10, 2026 SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty...